News

October 9, 2024

Dos estudios realizados en el CNIC aportan información relevante sobre un nuevo factor de riesgo cardiovascular, la hematopoyesis clonal, y su tratamiento con un fármaco ancestral, la colchicina A los ya conocidos factores de riesgo cardiovascular como la presión arterial alta, el...

March 13, 2024

Jose Javier Fuster, coordinator of atheroclonal, delivered a plenary lecture at the 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research celebrated in Vienna, Austria, from February 27th to March 1st. The Society of Thrombosis and Haemostasis Research...

November 15, 2023

Atheroclonal´s CNIC team, together with other CNIC researchers, has participated in the organization and presentation of Cardioguía, a dissemination event focused on educating the public about risk factors of cardiovascular disease and its prevention, celebrated last week at CNIC. Cardioguía...

July 13, 2023

ICREC group focuses on both basic and clinical research approaches to heart failure and cardiac regeneration. They work on the identification of prognostic factors and biomarkers of heart failure progression. Additionally, they have a translational focus, working also with stem...

July 13, 2023

The Biomedical Genomics (BBGLab) research group is focused on the study of cancer and somatic tissues in general from a genomics perspective. They have made major contributions in the identification of cancer genes and cancer driver mutations across tumor types;...

July 13, 2023

The Hematovascular Pathophysiology Laboratory is focused on evaluating new mechanisms that link clonal hematopoiesis to cardiovascular and metabolic disorders, with an especial interest in context of aging. Their research combines human studies, both cross-sectional and longitudinal, to elucidate the associations...
Skip to content